Cefiderocol Targeted Treatment for Multidrug-Resistant Gram-Negative Infections: An Observational Cohort Study
| dc.contributor.author | García Carnero, Lourdes | |
| dc.contributor.author | Abelenda Alonso, Gabriela | |
| dc.contributor.author | Santos Puig, Marc | |
| dc.contributor.author | Padullés Zamora, Ariadna | |
| dc.contributor.author | Ribera, Clara | |
| dc.contributor.author | Lamiel, Alberto | |
| dc.contributor.author | Costa Primo, Rosa Maria | |
| dc.contributor.author | González de Aledo, Manuel | |
| dc.contributor.author | Granada, Rosa | |
| dc.contributor.author | Gumucio, Víctor Daniel | |
| dc.contributor.author | Santafosta, Eva | |
| dc.contributor.author | Gilabert, Marc | |
| dc.contributor.author | Blanco Arévalo, Alejandro | |
| dc.contributor.author | Puig Asensio, Mireia | |
| dc.contributor.author | Shaw, Evelyn | |
| dc.contributor.author | Carratalà, Jordi | |
| dc.contributor.author | Gudiol González, Carlota | |
| dc.date.accessioned | 2026-07-02T12:24:06Z | |
| dc.date.available | 2026-07-02T12:24:06Z | |
| dc.date.issued | 2026-04-20 | |
| dc.date.updated | 2026-05-26T12:30:49Z | |
| dc.description.abstract | Background/Objectives: Infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) represent a major therapeutic challenge, particularly in hospitalized and critically ill patients with limited treatment options. Cefiderocol, a novel siderophore cephalosporin, has demonstrated activity against a broad range of resistant Gram-negative pathogens. We aimed to evaluate the effectiveness and safety of cefiderocol for the treatment of MDR-GNB infection. Methods: We conducted a retrospective observational study including all adult patients who received >= 72 h of cefiderocol between November 2020 and October 2024 at a Spanish tertiary-care hospital. The primary outcome was clinical success, defined as survival and absence of clinical recurrence 30 days after cefiderocol initiation. Secondary outcomes included 30- and 90-day mortality, clinical and microbiological recurrence, emergence of resistance, and adverse events. Results: Eighty patients were included (median age 64 years [IQR 56-72]; 81.3% male). Respiratory (26.2%) and abdominal (22.5%) infections were the most common, and 20% presented with bacteremia. At infection onset, 26.2% had septic shock and 45% required intensive care unit admission. The three most frequently isolated pathogen was Pseudomonas aeruginosa (33.9%), followed by Enterobacterales (33%) and Stenotrophomonas maltophilia (30.1%). Clinical success was achieved in 67.5% of patients. Thirty and 90-day mortality rates were 27.5% and 36.5%, respectively. Recurrence within 90 days occurred in 5% of cases. Emergence of resistance was detected in one Klebsiella pneumoniae ST147 isolate, and serious adverse events occurred in 5% of patients. Conclusions: In a cohort including a substantial proportion of critically ill patients, cefiderocol was associated with favorable clinical outcomes and an acceptable safety profile. These findings suggest that cefiderocol may represent a useful therapeutic option for severe MDR-GNB infections in patients with limited treatment alternatives. | |
| dc.format.extent | 12 p. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.issn | 2079-6382 | |
| dc.identifier.pmid | 42041379 | |
| dc.identifier.uri | https://hdl.handle.net/2445/230390 | |
| dc.language.iso | eng | |
| dc.publisher | MDPI AG | |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/antibiotics15040416 | |
| dc.relation.ispartof | Antibiotics, 2026, vol. 15, num. 4, p. 416 | |
| dc.relation.uri | https://doi.org/10.3390/antibiotics15040416 | |
| dc.rights | cc by (c) García Carnero, Lourdes et al., 2026 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | |
| dc.subject.classification | Cefalosporines | |
| dc.subject.classification | Malalts en estat crític | |
| dc.subject.classification | Resistència als medicaments | |
| dc.subject.other | Cephalosporines | |
| dc.subject.other | Critically ill | |
| dc.subject.other | Drug resistance | |
| dc.title | Cefiderocol Targeted Treatment for Multidrug-Resistant Gram-Negative Infections: An Observational Cohort Study | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
Fitxers
Paquet original
1 - 1 de 1
Carregant...
- Nom:
- antibiotics-15-00416.pdf
- Mida:
- 442.23 KB
- Format:
- Adobe Portable Document Format